Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
20.8M
-
Number of holders
-
222
-
Total 13F shares, excl. options
-
172M
-
Shares change
-
-973K
-
Total reported value, excl. options
-
$2.92B
-
Value change
-
-$16.1M
-
Put/Call ratio
-
0.38
-
Number of buys
-
100
-
Number of sells
-
-117
-
Price
-
$17.00
Significant Holders of Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) as of Q4 2020
286 filings reported holding NKTR - Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2020.
Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) has 222 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 172M shares
.
Largest 10 shareholders include Invesco Ltd. (35.5M shares), FMR LLC (18.9M shares), PRIMECAP MANAGEMENT CO/CA/ (18.4M shares), BlackRock Inc. (18.4M shares), VANGUARD GROUP INC (16.3M shares), WELLINGTON MANAGEMENT GROUP LLP (13.4M shares), MAVERICK CAPITAL LTD (6.66M shares), STATE STREET CORP (4.48M shares), Bellevue Group AG (3.87M shares), and FIRST TRUST ADVISORS LP (3.81M shares).
This table shows the top 222 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.